374
Participants
Start Date
February 23, 2013
Primary Completion Date
January 27, 2015
Study Completion Date
January 27, 2015
Albiglutide
Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
Sulfonylurea
Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Biguanide
Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Glinide
Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Thiazolidinedione
Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Alpha-glucosidase inhibitor
Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
GSK Investigational Site, Aichi
GSK Investigational Site, Chiba
GSK Investigational Site, Ehime
GSK Investigational Site, Fukuoka
GSK Investigational Site, Fukuoka
GSK Investigational Site, Fukuoka
GSK Investigational Site, Fukushima
GSK Investigational Site, Fukushima
GSK Investigational Site, Gunma
GSK Investigational Site, Gunma
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hokkaido
GSK Investigational Site, Ibaraki
GSK Investigational Site, Ibaraki
GSK Investigational Site, Kagawa
GSK Investigational Site, Kagoshima
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kochi
GSK Investigational Site, Kumamoto
GSK Investigational Site, Kumamoto
GSK Investigational Site, Kyoto
GSK Investigational Site, Kyoto
GSK Investigational Site, Kyoto
GSK Investigational Site, Miyagi
GSK Investigational Site, Miyagi
GSK Investigational Site, Nagano
GSK Investigational Site, Nagano
GSK Investigational Site, Okinawa
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Ōita
GSK Investigational Site, Saitama
GSK Investigational Site, Saitama
GSK Investigational Site, Saitama
GSK Investigational Site, Saitama
GSK Investigational Site, Saitama
GSK Investigational Site, Saitama
GSK Investigational Site, Shizuoka
GSK Investigational Site, Tochigi
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
Lead Sponsor
GlaxoSmithKline
INDUSTRY